Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ecotropic viral integration site 2A (EVI2A)
- Target
- EVI2A
- Molecular classification
- Transmembrane signaling receptor, Other (as its precise molecular function—receptor vs. accessory protein—remains incompletely characterized)
01
Overview
Ecotropic viral integration site 2A is a transmembrane protein encoded within the NF1 gene locus, predicted to function as part of a cell-surface signaling receptor. EVI2A is frequently overexpressed in several cancers and is associated with poor prognosis, mediating oncogenic effects via activation of the MEK/ERK pathway in osteosarcoma and possibly other solid tumors. It plays roles in cell proliferation, migration, and immune system modulation, and is considered a prognostic biomarker and potential therapeutic target in renal clear cell carcinoma, among other malignancies. Additionally, its methylation status and transcriptomic profile may help predict disease outcomes and response to immunotherapies. EVI2A may also be implicated in the severity of neurofibromatosis type I due to its genomic context.
- Other names
- EVDAEVI2EVI-2AProtein EVI2ALOC688044Ecotropic viral integration site 2A protein homolog
02
Mechanism of action
Modulation of MEK/ERK signaling pathway (in cancer); Predictive biomarker for immunotherapy (in renal cancer)
03
Biological functions
Signal transductionCell proliferationCell migrationImmune response modulationPrognostic biomarker (especially in cancer)
04
Disease associations
Cancer (e.g., osteosarcoma, kidney renal clear cell carcinoma, breast cancer, head and neck squamous cell carcinoma, cholangiocarcinoma)Neurofibromatosis type IInflammatory diseases (rheumatoid arthritis)
05
Safety considerations
Not explicitly reported; as a novel or emerging therapeutic target, potential off-target effects and impact on normal NF1 gene functions could be concerns (inferred)
06
Interacting drugs
Tyrosine kinase inhibitors (inferred from role in cancers and association with immunotherapy sensitivity; specific drugs not identified in search results)
1 more in the full profile.
07
Biomarkers
Expression and methylation status used as potential biomarkers for cancer prognosis (e.g., renal cell carcinoma, osteosarcoma)
Beyond the preview
Go deeper on Ecotropic viral integration site 2A (EVI2A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ecotropic viral integration site 2A (EVI2A).